Information on the contract are confidential.

Under the conditions of the license, Catalent will complete transfer of the technology into its world class, cGMP facilities to support produce of novel dosage forms such as for example its Zydis – fast dissolve system. It is anticipated that the taste-masking technology shall be effective for creating a wide selection of formulations including granules/sachets, sprinkles, chewables, oral and effervescent dispersible tablets. Continue reading